Radiation-induced second malignancies (RISM) is one of the important late side effects of
radiation therapy and has an impact on optimal treatment decision-making. Many factors …

Over the past 4 decades, basic research has provided crucial information regarding the
cellular and molecular biology of cancer. In particular, the relevance of cancer …

PURPOSE CARTITUDE-1, a phase Ib/II study evaluating the safety and efficacy of
ciltacabtagene autoleucel (cilta-cel) in heavily pretreated patients with relapsed/refractory …

Background CARTITUDE-1 aimed to assess the safety and clinical activity of ciltacabtagene
autoleucel (cilta-cel), a chimeric antigen receptor T-cell therapy with two B-cell maturation …

Purpose Lenalidomide maintenance therapy after autologous stem-cell transplantation
(ASCT) demonstrated prolonged progression-free survival (PFS) versus placebo or …

Background Lenalidomide plus dexamethasone is a reference treatment for patients with
newly diagnosed myeloma. The combination of the proteasome inhibitor bortezomib with …

PURPOSE To provide evidence-based recommendations on the treatment of multiple
myeloma to practicing physicians and others. METHODS ASCO and Cancer Care Ontario …

Background The combination melphalan–prednisone–thalidomide (MPT) is considered a
standard therapy for patients with myeloma who are ineligible for stem-cell transplantation …

Multiple myeloma is a malignant neoplasm of plasma cells that accumulate in bone marrow,
leading to bone destruction and marrow failure. This manuscript discusses the management …

PURPOSE Single-cycle melphalan 200 mg/m 2 and autologous hematopoietic cell
transplantation (AHCT) followed by lenalidomide (len) maintenance have improved …